Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies

BACKGROUND: Overexpression/activation of focal adhesion kinase (FAK) in human malignancies has led to its evaluation as a therapeutic target. We report the first-in-human phase I study of BI 853520, a novel, potent, highly selective FAK inhibitor. OBJECTIVE: Our objectives were to identify the maxim...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Target Oncol
Main Authors: de Jonge, Maja J. A., Steeghs, Neeltje, Lolkema, Martijn P., Hotte, Sebastien J., Hirte, Hal W., van der Biessen, Diane A. J., Abdul Razak, Albiruni R., De Vos, Filip Y. F. L., Verheijen, Remy B., Schnell, David, Pronk, Linda C., Jansen, Monique, Siu, Lillian L.
Format: Artigo
Jezik:Inglês
Izdano: Springer International Publishing 2019
Teme:
Original Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6407740/
https://ncbi.nlm.nih.gov/pubmed/30756308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-018-00617-1
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki